ArticleHealth affairs scholar2026
ICER's launch price and access report: 5 key takeaways and 5 questions we should all be asking.
Article in Health affairs scholar, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improving prescription drug affordability and patient access remains a key policy objective in the US health care system, yet not every proposed solution will help us achieve this goal. To contribute to this ongoing policy discussion, the Institute for Clinical and Economic Review (ICER) published a report in October 2025 to evaluate the launch prices of new Food and Drug Administration (FDA)-approved drugs and patient access to those therapies. This article highlights five key takeaways from the report and proposes five critical questions for consideration. Based on findings from ICER's Launch Price and Access report, this article offers key recommendations to move the US health care system toward one that pays for value and delivers affordable access for patients, while driving the next wave of innovation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.